A Phase 2 study of Darifenacin in ALS
Recruiting Phase 2 NCT06249867
Study Description
A study to evaluate the safety and effects of the drug Darifenacin in patients with Amyotrophic Lateral Sclerosis (ALS)
Study Details
- Registry ID:
- NCT06249867
- Conditions:
- Amyotrophic Lateral Sclerosis
- Phase:
- Phase 2
- Target Enrollment:
- 30 participants
- Start Date:
- Age Range:
- 18–85 years
- Healthy Volunteers:
- No
Study Locations (2 sites)
-
Montreal Neurological Institute
Montréal, Quebec, Canada -
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.